Association of Ocular Antihypertensive Medications and the Development and Progression of Age-related Macular Degeneration in a U.S. Insurance Claims Database

References

• Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, Friedman DS, Keeffe JE, Kempen JH, LeasherJ, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5):575–85. doi:10.1136/bjophthalmol-2017-311258.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–59. doi:10.1016/S0140-6736 (18)31550-2.
   PubMed Web of Science ®Google Scholar
• Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75–80. doi:10.1001/archophthalmol.2010.318.
   PubMedGoogle Scholar
• Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: asystematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi:10.1016/S2214-109X(13)70145-1.
   PubMed Web of Science ®Google Scholar
• Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108(10):1893–900. doi:10.1016/S0161-6420 (01)00754-0.
   PubMed Web of Science ®Google Scholar
• Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079–91. doi:10.1016/j.ophtha.2013.11.023.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Bailey CC, Johnston RL, McKibbin M, Khan RS, Mahmood S, Downey L, Dhingra N, Brand C, Brittain CJ, et al. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(6):842–49. doi:10.1016/j.ophtha.2017.11.036.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: asystematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. doi:10.1016/j.ophtha.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Kingman S. Glaucoma is thesecond leading cause of blindness globally. Bull World Health Organ. 2004;82:887–88.
   PubMed Web of Science ®Google Scholar
• Sridhar J, Hsu J, Shahlaee A, Garg SJ, Spirn MJ, Fineman MS, Vander J. Topical dorzolamide-timolol with intravitreous anti–vascular endothelial growth factor for neovascular age-related macular degeneration. JAMA Ophthalmol. 2016;134(4):437–43. doi:10.1001/jamaophthalmol.2016.0045.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SC, Byeon SH, Koh HJ, Kim SS, Lee CS. Efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor therapy. Retina. 2019;39(10):1953–58. doi:10.1097/IAE.0000000000002293.
   PubMed Web of Science ®Google Scholar
• Hsu J, Patel SN, Wolfe JD, Shah CP, Chen E, Jenkins TL, Wibbelsman TD, Obeid A, Mikhail M, Garg SJ, et al. Effect of adjuvant topical dorzolamide-timolol vs placebo in neovascular age-related macular degeneration: arandomized clinical trial. JAMA Ophthalmol. 2020;138(5):560. Epub ahead of print. doi:10.1001/jamaophthalmol.2020.0724.
   PubMed Web of Science ®Google Scholar
• Freeman WR. Brimonidine DDS safety and efficacy in patients with geographic atrophy secondary to age-related macular degeneration. Oral presentation at: AAO Annual Meeting, Retina Subspecialty Day; 2018; Chicago, IL.
   Google Scholar
• World Health Organization. International classification of diseases. Jun 18, 2018.
   Google Scholar
• Kolomeyer AM, Maguire MG, Pan W, VanderBeek BL. Systemic beta-blockers and risk of progression to neovascular age-related macular degeneration. Retina. 2019;39(5):918–25. doi:10.1097/IAE.0000000000002059.
   PubMed Web of Science ®Google Scholar
• Allergan: asafety and efficacy study of brimonidine intravitreal implant in geographic atrophy secondary to age-related macular degeneration (BEACON). https://clinicaltrials.gov/ct2/show/NCT02087085. NLM identifier: NCT02087085. [Accessed Jun 10, 2019].
   Google Scholar
• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver dam eye study. Ophthalmology. 1992;99(6):933–43. doi:10.1016/S0161-6420 (92)31871-8.
   PubMed Web of Science ®Google Scholar
• Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ. The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study. Ophthalmology. 2015;122(12):2482–89. doi:10.1016/j.ophtha.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205–10. doi:10.1016/S0161-6420 (95)31034-2.
   PubMed Web of Science ®Google Scholar
• Klein R, Clegg L, Cooper LS, Hubbard LD, Klein BE, King WN, Folsom AR. Prevalence of age-related maculopathy in the atherosclerosis risk in communities study. Arch Ophthalmol. 1999;117(9):1203–10. doi:10.1001/archopht.117.9.1203.
   PubMedGoogle Scholar
• Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, Liu K, Burke G, Saad MF, Jacobs DR Jr. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113(3):373–80. doi:10.1016/j.ophtha.2005.12.013.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999;106(6):1049–55. doi:10.1016/S0161-6420 (99)90267-1.
   PubMed Web of Science ®Google Scholar
• Vanderbeek BL, Zacks DN, Talwar N, Nan B, Musch DC, Stein JD. Racial differences in age-related macular degeneration rates in the United States: alongitudinal analysis of amanaged care network. Am J Ophthalmol. 2011;152(2):273–82.e3. doi:10.1016/j.ajo.2011.02.004.
   PubMed Web of Science ®Google Scholar
• Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors invivo and ameliorate light damage. J Neurosci. 1996;16(19):5986–92. doi:10.1523/JNEUROSCI.16-19-05986.1996.
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–55.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol. 2011;22(2):78–86. doi:10.1097/ICU.0b013e32834372ec.
   PubMed Web of Science ®Google Scholar
• Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127(4):402–06. doi:10.1001/archophthalmol.2009.9.
   PubMed Web of Science ®Google Scholar
• Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850–58. doi:10.1016/j.ajo.2005.12.030.
   PubMed Web of Science ®Google Scholar
• Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol. 2010;128(2):190–97. doi:10.1001/archophthalmol.2009.398.
   PubMedGoogle Scholar
• Adijanto J, Philp NJ. The SLC16A family of monocarboxylate transporter (MCTs)–physiology and function in cellular metabolism, pH homeostasis, and fluid transport. Curr Top Membr. 2012;70:275–311.
   PubMed Web of Science ®Google Scholar
• Han JYS, Kinoshita J, Bisetto S, Bell BA, Nowak RA, Peachey NS, Philp NJ. Role of monocarboxylate transporters in regulating metabolic homeostasis in the outer retina: insight gained from the cell specific Bsg deletion. Faseb J. 2020;34(4):5401–19. doi:10.1096/fj.201902961R.
   PubMed Web of Science ®Google Scholar
• Polska E, Doelemeyer A, Luksch A, Ehrlich P, Kaehler N, Percicot CL, Lambrou GN, Schmetterer L. Partial antagonism of endothelin 1–induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol. 2002;120(3):348–52. doi:10.1001/archopht.120.3.348.
   PubMedGoogle Scholar
• Grunwald JE, Hariprasad SM, DuPont J, Maguire MG, Fine SL, Brucker AJ, Maguire AM, Ho AC. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998;39:385–90.
   PubMed Web of Science ®Google Scholar
• Xu W, Grunwald JE, Metelitsina TI, DuPont JC, Ying GS, Martin ER, Dunaief JL, Brucker AJ. Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol. 2010;150(1):40–39.e2. doi:10.1016/j.ajo.2010.01.041.
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Diehm C, Grieger F, Bentz J. Alprostadil infusion in patients with dry age related macular degeneration: arandomized controlled clinical trial. Expert Opin Investig Drugs. 2013;22(7):803–12. doi:10.1517/13543784.2013.794782.
   PubMed Web of Science ®Google Scholar
• Scherer WJ. Association between topical prostaglandin analog use and development of choroidal neovascular membranes in patients with concurrent glaucoma and age-related macular degeneration. J Ocul Pharmacol Ther. 2006;22(2):139–44. doi:10.1089/jop.2006.22.139.
   PubMed Web of Science ®Google Scholar
• Ghaem Maralani H, Tai BC, Wong TY, Tai ES, Li J, Wang JJ, Mitchell P. Metabolic syndrome and risk of age-related macular degeneration. Retina. 2015;35(3):459–66. doi:10.1097/IAE.0000000000000338.
   PubMed Web of Science ®Google Scholar
• Scott WK, Schmidt S, Hauser MA, Gallins P, Schnetz-Boutaud N, Spencer KL, Gilbert JR, Agarwal A, Postel EA, Haines JL, et al. Independent effects of complement factor HY402H polymorphism and cigarette smoking on risk of age-related macular degeneration. Ophthalmology. 2007;114(6):1151–56. doi:10.1016/j.ophtha.2006.08.054.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–15. doi:10.1001/jama.2013.4997.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. Arandomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins Cand E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–36. doi:10.1001/archopht.119.10.1417.
   PubMed Web of Science ®Google Scholar
• Hu CC, Ho JD, Lin HC, Kao LT. Association between open-angle glaucoma and neovascular age-related macular degeneration: a case-control study. Eye(Lond). 2017;31(6):872–77. doi:10.1038/eye.2016.325.
   Google Scholar